A karyotype test examines whole chromosomes under a microscope to evaluate their number and large-scale structure. It can identify an extra or missing chromosome, a large deletion or duplication, a balanced or unbalanced translocation, an inversion, a ring chromosome, and some forms of mosaicism. Karyotyping remains important because it shows chromosome architecture in a way that DNA sequencing and chromosomal microarray may not. It is used in prenatal diagnosis, evaluation of congenital or reproductive conditions, pregnancy-loss testing, and the diagnosis and risk assessment of blood cancers. The test requires dividing cells, so cells often must be cultured before chromosomes can be stained and analyzed. A normal result does not exclude smaller copy-number changes, single-gene variants, or low-level mosaicism. An abnormal result may be constitutional, meaning present from conception, or acquired in a tumor. Correct interpretation therefore depends on the specimen, reason for testing, resolution, number of cells examined, and exact chromosome notation.
- Karyotyping counts chromosomes and evaluates large structural changes visible by banding.
- It can detect balanced rearrangements that chromosomal microarray generally cannot identify.
- Most tests require living, dividing cells and may take longer than rapid molecular assays.
- Resolution is limited; small deletions, duplications, and gene variants can be missed.
- Mosaic results depend on the tissue tested and the number of cells analyzed.
- Cancer karyotypes describe acquired clones and are interpreted differently from constitutional results.
Table of Contents
- What a karyotype shows
- Why the test is ordered
- How chromosome analysis is performed
- How to read karyotype notation
- Types of abnormal results
- Mosaicism, variants, and uncertain findings
- Limitations and complementary tests
- Next steps after a result
What a Karyotype Shows
Human chromosomes contain long molecules of DNA packaged with proteins. Most cells have 46 chromosomes arranged as 22 pairs of autosomes and one pair of sex chromosomes. A karyotype is an organized image and description of chromosomes captured while they are condensed during cell division. Their size, centromere position, and light-and-dark banding patterns allow a cytogeneticist to identify each chromosome and look for major abnormalities.
Karyotyping is especially good at answering two broad questions: Is the chromosome number normal, and is the large-scale arrangement of chromosome material normal? Numerical abnormalities include trisomy, in which an extra chromosome is present, and monosomy, in which one copy is missing. Structural abnormalities include translocations, inversions, large deletions or duplications, rings, isochromosomes, dicentric chromosomes, and marker chromosomes.
A major strength is the ability to recognize balanced rearrangements. In a balanced reciprocal translocation, segments from two chromosomes exchange places without an obvious net loss or gain of material. A carrier may be healthy but have reproductive risks because eggs or sperm can receive an unbalanced chromosome combination. A chromosomal microarray detects gains and losses at much higher resolution but usually cannot show a truly balanced translocation or inversion. Karyotype and microarray therefore answer overlapping but not identical questions.
The test’s resolving power is described by band level. A higher-band study shows more bands and can identify smaller structural changes than a lower-band study, but conventional karyotyping still has far less resolution than microarray or sequencing. In constitutional testing, abnormalities typically must span millions of DNA bases to be visible, although the practical limit varies with chromosome region, band quality, and rearrangement type [1].
A karyotype also provides cellular context. It can show whether all examined cells share an abnormality or whether two or more cell lines are present. In cancer, it can reveal several related abnormalities within the same clone, helping reconstruct clonal evolution. This whole-chromosome view remains valuable even in an era of genome-wide molecular tests.
Why the Test Is Ordered
Karyotyping may be requested for constitutional, prenatal, reproductive, pregnancy-loss, or cancer-related reasons. The clinical indication determines the specimen, culture method, number of cells examined, and how the finding is interpreted.
Constitutional evaluation: A blood karyotype may be used when a clinician suspects a common aneuploidy or a large chromosome rearrangement. Examples include features suggestive of Down syndrome, Turner syndrome, Klinefelter syndrome, or another sex-chromosome condition. It may also be used for primary amenorrhea, delayed puberty, infertility, recurrent pregnancy loss, or a family history of a balanced rearrangement. For many individuals with developmental delay, intellectual disability, autism, or multiple congenital anomalies, microarray or genome-scale testing is generally more sensitive for small imbalances; karyotyping is selected when a large rearrangement or aneuploidy is specifically suspected.
Prenatal diagnosis: Karyotyping can be performed on chorionic villus or amniotic-fluid cells after an abnormal screening result, ultrasound finding, family history, or parental rearrangement. Screening tests such as prenatal cell-free DNA estimate the chance of selected chromosome conditions; they do not replace diagnostic analysis of fetal or placental cells. A prenatal karyotype can confirm aneuploidy and show whether an extra chromosome is free-standing or caused by a translocation, which changes recurrence counseling [2].
Pregnancy loss: Products of conception may be tested to identify a chromosome abnormality that explains a miscarriage or fetal loss. Culture failure and maternal-cell contamination can complicate conventional analysis, so some laboratories use microarray or other methods. Karyotype remains useful when balanced or whole-chromosome architecture is important.
Cancer: Bone marrow, blood, lymph node, or tumor tissue may be cultured to detect acquired chromosome changes. In leukemia, myelodysplastic syndromes, plasma-cell neoplasms, and some lymphomas, the karyotype can contribute to diagnosis, prognostic classification, treatment selection, and response assessment. Cancer classifications increasingly incorporate genomic findings, but conventional cytogenetics still identifies complex karyotypes and clonal abnormalities with established risk significance [3].
Family studies: When a child or pregnancy has an unbalanced rearrangement, parental karyotyping can determine whether it arose de novo or was inherited from a balanced carrier. That distinction can substantially change recurrence estimates and options for future pregnancies.
How Chromosome Analysis Is Performed
The laboratory needs cells that can divide. Peripheral-blood lymphocytes are commonly stimulated to enter the cell cycle. Amniotic-fluid cells, chorionic villus cells, skin fibroblasts, bone marrow cells, and solid-tumor cells may require different culture conditions. Some cancer cells divide spontaneously, while other specimens grow poorly.
After an appropriate culture period, the laboratory arrests cells in metaphase, when chromosomes are condensed and visible. The cells are treated so they swell, fixed onto microscope slides, and stained. Giemsa banding, or G-banding, produces a characteristic pattern of alternating light and dark regions. A technologist examines metaphase cells, counts chromosomes, and compares their banding patterns. Selected metaphases are digitally arranged into a karyogram.
The number of cells analyzed depends on the indication and laboratory standard. A routine constitutional study may fully analyze a defined number of metaphases and count additional cells. More cells may be examined when mosaicism is suspected. Cancer studies often analyze multiple metaphases to determine whether an abnormality is clonal. A laboratory may add targeted FISH testing when cells do not divide well, a rapid answer is needed, or a particular rearrangement requires confirmation.
Turnaround time is influenced by how quickly cells grow. Blood cultures may produce metaphases within several days, whereas amniotic fluid, fibroblast, or some tumor cultures can take longer. Failure is possible when the specimen contains too few viable cells, arrives late, is contaminated, or does not divide. A culture failure is not a normal result; it means the intended analysis could not be completed.
Quality is more than the number of metaphases. Cytogeneticists assess band resolution, chromosome overlap, cell morphology, and consistency across cells. Formal guidelines address acceptable analysis, reporting, and follow-up for prenatal, postnatal, pregnancy-loss, and solid-tissue samples [1].
The report should identify the specimen and usually includes the International System for Human Cytogenomic Nomenclature, or ISCN, description. It may state the number of cells counted, analyzed, or karyotyped, the band level, and whether supplementary methods were used. In oncology, it may list multiple clones separated within the notation and describe the proportion of metaphases in each clone.
How to Read Karyotype Notation
Karyotype notation is compact and can look intimidating. It is designed for laboratory precision, not as a stand-alone patient explanation. The first number is the total chromosome count, followed by the sex-chromosome complement, then any abnormalities.
| Example | Plain-language meaning |
|---|---|
46,XX | 46 chromosomes with two X chromosomes; no visible abnormality reported |
46,XY | 46 chromosomes with one X and one Y; no visible abnormality reported |
47,XX,+21 | An extra chromosome 21 in a cell line with two X chromosomes |
45,X | One X chromosome and no second sex chromosome |
46,XY,t(11;22)(q23;q11.2) | A translocation between chromosomes 11 and 22 with stated breakpoints |
46,XX,inv(9)(p11q13) | An inversion involving chromosome 9 |
mos 45,X[12]/46,XX[18] | Mosaic result: 12 cells with 45,X and 18 cells with 46,XX |
Common abbreviations include del for deletion, dup for duplication, t for translocation, inv for inversion, r for ring chromosome, i for isochromosome, der for derivative chromosome, and mar for a marker chromosome. The letters p and q refer to the short and long chromosome arms. Numbers after them identify bands and sub-bands.
Square brackets often show how many cells had a finding. In a cancer report, the first clone may be followed by related subclones and a normal cell line. A plus sign can indicate an extra whole chromosome or additional material, while a minus sign can indicate loss. Cancer notation can become very complex because one clone may contain multiple gains, losses, and structural rearrangements.
A “normal” notation means no abnormality was visible at the method’s resolution in the analyzed cells. It does not guarantee that every cell in the body has the same chromosome complement, nor does it exclude smaller pathogenic variants. Similarly, a balanced notation describes apparent balance at karyotype resolution; cryptic gains or losses at breakpoints can sometimes be found by microarray or sequencing.
Laboratory narrative interpretation is as important as the formula. It should explain the expected clinical association, whether the finding appears constitutional or acquired, whether parental studies are suggested, and which limitations apply. Patients should not try to infer prognosis or reproductive risk from notation alone.
Types of Abnormal Results
Aneuploidy means an abnormal number of individual chromosomes. Trisomy 21 causes Down syndrome, while trisomy 18 and trisomy 13 cause other recognizable syndromes. Sex-chromosome aneuploidies include 45,X and complements with an additional X or Y. Clinical effects vary, particularly for mosaic sex-chromosome findings.
Polyploidy means an extra complete set of chromosomes, such as triploidy. It is a common cause of pregnancy loss and is usually not compatible with long-term survival. Some cancer cells also become polyploid as part of genomic instability, but oncology interpretation differs from constitutional diagnosis.
Deletions and duplications remove or add a visible chromosome segment. Their impact depends on size, location, genes involved, and whether the change is present in all cells. Karyotyping may detect a large deletion but cannot define its exact DNA boundaries. Follow-up microarray often refines the size and gene content.
Translocations move chromosome material to a new location. A balanced reciprocal translocation may cause no health problem in a carrier but can disrupt a gene or create reproductive risk. A Robertsonian translocation joins the long arms of certain acrocentric chromosomes and can be associated with Down syndrome or pregnancy loss. An unbalanced translocation includes a gain or loss of material and may cause congenital anomalies or developmental effects.
Inversions occur when a chromosome segment breaks, reverses, and reinserts. A balanced inversion carrier may be healthy, but reproductive risk depends on the chromosome and size of the inverted segment. Some inversions are common benign variants; others disrupt genes or are acquired cancer drivers.
Ring and marker chromosomes can be more difficult to interpret. A ring forms when chromosome ends join, often with loss of terminal material. Rings may be unstable during cell division, producing mosaicism. A small marker chromosome is extra material that cannot be identified confidently by banding alone. FISH or microarray may be needed to determine its origin and gene content.
Cancer abnormalities are acquired rather than inherited in most cases. Recurrent translocations can create fusion genes, while loss of chromosomes or chromosome arms can indicate prognosis. A “complex karyotype” generally means multiple independent abnormalities, but the exact definition and risk implication depend on the cancer. The result must be interpreted under current disease-specific criteria rather than as a constitutional syndrome.
Mosaicism, Variants, and Uncertain Findings
Mosaicism means two or more genetically different cell populations developed from one fertilized egg. A karyotype can detect mosaicism when abnormal and normal cells are both present among the metaphases examined. The reported percentage is the proportion in the tested sample, not necessarily the proportion in every organ.
Detection depends on tissue and cell count. Blood may be normal even when another tissue contains the abnormal line, and some cell lines have a growth advantage or disadvantage in culture. Low-level mosaicism can be missed if only a limited number of cells are examined. When clinical suspicion remains high, the laboratory may analyze additional cells, test another tissue such as skin fibroblasts or buccal cells, or use FISH or molecular methods.
Prenatal mosaicism needs particular care. A mosaic result in chorionic villi may be confined to the placenta rather than present in the fetus. Follow-up amniocentesis may be recommended because it samples a different fetal-associated compartment. Maternal-cell contamination and culture artifact must also be considered. The meaning depends on which placental cell layer was tested, the abnormality, and whether it appears in direct and cultured preparations.
Some visible chromosome features are benign heteromorphisms—normal variations in repetitive or heterochromatic regions. Modern reports may avoid emphasizing variants with no established clinical consequence. A finding that appears balanced can still be uncertain when it is de novo, disrupts a potentially relevant gene, or contains cryptic imbalance. Higher-resolution testing may be recommended.
In cancer, clone definition follows cytogenetic rules. A change seen in enough metaphases may be considered clonal, while a single abnormal cell may be nonclonal or technically uncertain depending on the abnormality. The proportions can be influenced by culture and should not be treated as an exact measurement of tumor burden. Molecular minimal-residual-disease assays are usually more sensitive for monitoring a known target.
Genetic counseling is especially useful for mosaic, balanced, marker, and de novo results because laboratory wording may not translate directly into an individual prediction. Phenotype, ultrasound findings, family history, and additional testing often determine the practical meaning.
Limitations and Complementary Tests
A karyotype is a broad but low-resolution test. It does not sequence genes and usually cannot detect small deletions or duplications, single-nucleotide variants, small insertions or deletions, repeat expansions, methylation abnormalities, or most mitochondrial variants. It may miss subtle rearrangements, low-level mosaicism, and abnormalities in cells that fail to grow in culture.
The principal complementary tests are selected according to the unanswered question:
- Chromosomal microarray detects submicroscopic copy-number gains and losses and, on SNP-based platforms, regions of homozygosity. It generally does not detect balanced rearrangements.
- FISH rapidly tests a specific chromosome region or rearrangement and can analyze nondividing cells, but it only evaluates the probes used.
- Rapid aneuploidy testing by quantitative fluorescence PCR or targeted FISH can provide fast prenatal information for selected chromosomes, followed by broader testing when indicated.
- Gene panels, exome, or genome sequencing detect smaller sequence variants and may identify some structural changes, with capability varying by assay.
- RNA testing can establish whether a cancer rearrangement produces an expressed fusion transcript.
A normal karyotype after recurrent pregnancy loss does not exclude other genetic, uterine, endocrine, or immune-related contributors. A normal fetal karyotype does not exclude all genetic syndromes or birth defects. A normal bone-marrow karyotype does not exclude malignancy, because the clone may be small, nondividing, or defined by a molecular change below cytogenetic resolution.
Conversely, a clearly abnormal karyotype may still need refinement. Microarray can define the extent of visible imbalance, and FISH can identify marker material or confirm a suspected rearrangement. Genome sequencing may characterize breakpoints and disrupted genes. The appropriate sequence of tests depends on whether speed, balance, breakpoint precision, tissue availability, or breadth is most important.
Next Steps After a Result
For a normal result, confirm that the test addressed the original question. Ask what specimen was tested, what band resolution was achieved, how many cells were examined, and whether mosaicism or culture failure limited interpretation. If the phenotype remains unexplained, a genetics professional can recommend higher-resolution or sequence-based testing rather than repeating the same assay without a specific reason.
For an abnormal constitutional or prenatal result, the next steps often include:
- Review of the exact chromosome finding and expected range of effects.
- Genetic counseling that incorporates medical and family history.
- Parental karyotypes when an unbalanced or apparently balanced rearrangement is found.
- Microarray, FISH, or sequencing to clarify breakpoints or identify cryptic imbalance.
- Disease-specific evaluation, imaging, or surveillance when appropriate.
- Discussion of recurrence risk and reproductive options based on whether the finding is inherited or de novo.
A balanced carrier’s reproductive risk cannot be estimated from the word “balanced” alone. It depends on the chromosomes, breakpoints, carrier’s sex, prior pregnancies, and family experience. Options may include natural conception with prenatal diagnosis, preimplantation genetic testing for structural rearrangements, donor gametes, or other family-building approaches. Counseling should be nondirective.
For an oncology result, the hematologist or oncologist integrates the clone with morphology, immunophenotyping, FISH, and molecular tests. Ask whether the abnormality defines the diagnosis, changes risk category, influences treatment, or provides a marker for follow-up. A tumor karyotype usually does not imply that relatives should be tested. If the pattern or personal history raises concern for a germline predisposition, a separate constitutional specimen and genetics evaluation are needed.
Retain the full report. Future comparison may show whether a cancer clone disappears, persists, or evolves, and reproductive or prenatal counseling may require the exact breakpoints. Chromosome nomenclature can be technical, but the clinical interpretation should ultimately answer three practical questions: what was found, how certain is it, and what decision does it change?
References
- Karyotype Genetic Test. 2025. Patient laboratory guide.
- ACGS Best Practice Guidelines for Constitutional Karyotype Analysis and Targeted Chromosome Analysis. 2024. Professional guideline.
- Genetics, Cytogenetic Testing and Conventional Karyotype. 2023. Clinical review.
- Prenatal Testing for Chromosomal Abnormalities and Neural Tube Defects. 2025. Clinical testing guidance.
- ACMG Technical Standard Section E6.7-6.12: Clinical Cytogenomic Studies of Solid Tumors. 2024. Technical standard.
Disclaimer
This article is for general education and cannot interpret an individual constitutional, prenatal, reproductive, or cancer karyotype. Chromosome results can have medical and family implications, so review them with the ordering clinician, a board-certified laboratory specialist, and a genetic counselor when appropriate. Urgent cancer or prenatal decisions should use the complete report and current specialist guidance.
